[Clinical evaluation of sultamicillin fine granules in pediatric infections]. 1988

H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
Department of Pediatrics, School of Medicine, Teikyo University.

Sultamicillin fine granules (SBTPC), a mutual prodrug of sulbactam (SBT) and ampicillin (ABPC), were administered to 16 pediatric patients with bacterial infections. The efficacy rate was 93.3%. MICs (10(6) cells/ml) of SBTPC against beta-lactamase non-producing strains were not significantly different from those of ABPC, and ranged from less than or equal to 0.05 to 1.56 micrograms/ml. MICs of SBTPC, however, were 2-4 fold smaller than MICs of ABPC against beta-lactamase producing strains. Diarrhea and loose stool as side effects were observed in 4 (25%) of 16 patients, but none of them were severe. After oral administration of SBTPC (10 mg/kg), serum levels of ABPC and SBT peaked at 3.41 micrograms/ml and 2.43 micrograms/ml after 0.6 hour, and declined with half-lives of 1.79 and 1.00 hours, respectively.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000667 Ampicillin Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. Penicillin, Aminobenzyl,Amcill,Aminobenzylpenicillin,Ampicillin Sodium,Ampicillin Trihydrate,Antibiotic KS-R1,Omnipen,Pentrexyl,Polycillin,Ukapen,Aminobenzyl Penicillin,Antibiotic KS R1,KS-R1, Antibiotic,Sodium, Ampicillin,Trihydrate, Ampicillin
D000668 Ampicillin Resistance Nonsusceptibility of a microbe to the action of ampicillin, a penicillin derivative that interferes with cell wall synthesis. Ampicillin Resistances,Resistance, Ampicillin,Resistances, Ampicillin

Related Publications

H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
August 1989, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
September 1994, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
H Meguro, and O Arimasu, and F Hiruma, and N Sugie, and S Nishimura, and T Abe, and R Fujii, and J Mashiko, and Y Nagao, and Y Okamoto
December 1988, The Japanese journal of antibiotics,
Copied contents to your clipboard!